Rate My Professor Oliver Oey

His research specializations center on medical oncology, encompassing melanoma, colorectal cancer, urological cancers including prostate and bladder cancer, breast cancer, stromal inflammation, and emerging diagnostic and therapeutic approaches like extracellular vesicles and nanoparticles. Oey has co-authored over 20 peer-reviewed publications, with a total of 103 citations on ResearchGate. Key publications include "Application of extracellular vesicles in the diagnosis and treatment of prostate cancer: Implications for clinical practice" (2021), which discusses the clinical potential of extracellular vesicles; "Patient human leukocyte antigen (HLA) genotype may predict response to anti-programmed death receptor 1 (anti-PD1) in advanced melanoma" (2021); "Gut microbiota diversity and composition in predicting response to immune checkpoint inhibitors in melanoma" (2022); "Anterior pelvic exenteration and synchronous bilateral salpingo-oophorectomy" (2022); "Stromal inflammation, fibrosis and cancer: An old intuition with new insights" (2023); "Total neoadjuvant therapy for locally advanced rectal cancer: A western Australian experience" (2023); "Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial bladder cancer" (2024); "Eribulin in breast cancer: Current insights and therapeutic perspectives" (2024); and "Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Insights from the Western Australian Context" (2024). He has presented research at international conferences including the American Society of Clinical Oncology and American Association for Cancer Research meetings, underscoring his growing influence in oncology research.